145 related articles for article (PubMed ID: 38520216)
21. Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer.
Liu Y; Liu S; Yan L; Zhang Q; Liu W; Huang X; Liu S
Mediators Inflamm; 2023; 2023():1400267. PubMed ID: 38022687
[TBL] [Abstract][Full Text] [Related]
22. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
23. The Value of the Stemness Index in Ovarian Cancer Prognosis.
Yuan H; Yu Q; Pang J; Chen Y; Sheng M; Tang W
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741755
[TBL] [Abstract][Full Text] [Related]
24. A novel extrachromosomal circular DNA related genes signature for overall survival prediction in patients with ovarian cancer.
Zhang Y; Dong K; Jia X; Du S; Wang D; Wang L; Qu H; Zhu S; Wang Y; Wang Z; Zhang S; Sun W; Fu S
BMC Med Genomics; 2023 Jun; 16(1):140. PubMed ID: 37337170
[TBL] [Abstract][Full Text] [Related]
25. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
27. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
28. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
Feng J; Yu Y; Yin W; Qian S
J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
[TBL] [Abstract][Full Text] [Related]
29. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer.
Wang Z; Zhang J; Dai F; Li B; Cheng Y
J Ovarian Res; 2023 Jan; 16(1):12. PubMed ID: 36642706
[TBL] [Abstract][Full Text] [Related]
31. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
32. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
Duan Y; Xu X
Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
[TBL] [Abstract][Full Text] [Related]
33. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
34. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
Zheng J; Guo J; Zhu L; Zhou Y; Tong J
J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
[TBL] [Abstract][Full Text] [Related]
36. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer.
Nie S; Ni N; Chen N; Gong M; Feng E; Liu J; Liu Q
J Ovarian Res; 2023 Apr; 16(1):82. PubMed ID: 37095524
[TBL] [Abstract][Full Text] [Related]
37. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis reveals a four-gene signature for predicting survival and immunotherapy response in colon cancer patients using bulk and single-cell RNA-seq data.
Chai R; Zhao Y; Su Z; Liang W
Front Oncol; 2023; 13():1277084. PubMed ID: 38023180
[TBL] [Abstract][Full Text] [Related]
39. Identification and Validation of NK Marker Genes in Ovarian Cancer by scRNA-seq Combined with WGCNA Algorithm.
He X; Feng W
Mediators Inflamm; 2023; 2023():6845701. PubMed ID: 37144238
[TBL] [Abstract][Full Text] [Related]
40. Construction of a novel prognostic-predicting model correlated to ovarian cancer.
Tang W; Li J; Chang X; Jia L; Tang Q; Wang Y; Zheng Y; Sun L; Feng Z
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32716025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
